When social distancing was first implemented in March 2020 due to the COVID-19 pandemic, telemedicine appeared to be a temporary replacement for some healthcare visits. People still came in for appointments when in-person care was essential, but if the problem could be solved online, it was solved online. This raises the immediate question: if these problems can be solved online, why not keep solving them online? Historically, telemedicine has been impeded by three main barriers: applicability, lack of insurance coverage, and technology. However, with COVID and innovation as accelerators, telemedicine is breaking through.
HealthXL’s newest blog post featured perspectives from ER’s Bernice Ma and Todd Kolm on the future of Digital Health in 2021 after COVID-19. Here are the top predictions:
Why have commercial life sciences, with a track record of going it alone, pivoted to partnerships with the Digital Health Ecosystem? How might a life science marketer get their organization primed for more/better partnering? How is the success of a partnership measured? What are some of the key watchouts in partnering?
The social determinants of health are the conditions in which people are born, grow, live, work and age.1 You’ve probably seen or read the term in headlines, presented at conferences, or discussed at roundtables and meeting, but how are social determinants of health (SDoH) relevant to pharma?
Digital health is all the buzz these days, but how do you know which digital health opportunity is the best one to pursue for your brand or organization?
Pharma and digital health companies can both benefit from an effective and meaningful partnership.
Recent Comments